Fifth Third Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$556K Buy
3,920
+506
+15% +$81.3K 0.01% 483
2026
Q2
$575K Sell
3,414
-149
-4% -$22.1K 0.02% 447
2026
Q1
$469K Buy
3,563
+430
+14% +$57.1K 0.02% 445
2025
Q4
$444K Hold
3,133
– – 0.02% 430
2025
Q3
$440K Buy
3,133
+9
+0.3% +$1.22K 0.02% 423
2025
Q2
$393K Sell
3,124
-67
-2% -$7.68K 0.02% 434
2025
Q1
$353K Buy
3,191
+10
+0.3% +$1.27K 0.02% 435
2024
Q4
$434K Hold
3,181
– – 0.02% 371
2024
Q3
$367K Buy
3,181
+24
+0.8% +$3.29K 0.02% 392
2024
Q2
$435K Buy
+3,157
New +$433K 0.03% 301

Other funds holding NBIX

Fifth Third Wealth Advisors's NBIX Position: Q3 2026 in Review

Fifth Third Wealth Advisors increased its Neurocrine Biosciences (NBIX) stake by 15% in Q3 2026, buying an estimated $81.3K and bringing the position to 3,920 shares worth $556K. The position accounts for 0.01% of the portfolio, ranked #483.

Fifth Third Wealth Advisors first reported a position in NBIX in Q2 2024 and has held it in 10 quarters since. The position peaked at $575K in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Fifth Third Wealth Advisors held 3,920 shares of Neurocrine Biosciences worth $556K as of Q3 2026.
  • Fifth Third Wealth Advisors bought 506 Neurocrine Biosciences shares in Q3 2026, an estimated $81.3K.
  • Neurocrine Biosciences made up 0.01% of Fifth Third Wealth Advisors's portfolio in Q3 2026, its #483 holding.
  • Fifth Third Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 10 quarters since.
  • Fifth Third Wealth Advisors's Neurocrine Biosciences position peaked at $575K in Q2 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q3 2026, filed 22 Oct 2026.